Open Access<p>Pseudoprogression After Palbociclib with Aromatase Inhibitors Treatment in Metastatic Breast Cancer</p>
Author(s) -
Weiwei Huang,
Chao Li,
Mulan Chen,
Dongdong Lin,
Fengjie Wu,
Xinhua Chen,
Nani Li,
Lili Wang,
Jian Liu
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s253333
Subject(s) - medicine , palbociclib , breast cancer , metastatic breast cancer , oncology , radiation therapy , cancer , aromatase
A 62-year-old postmenopausal woman was diagnosed with breast cancer in her left breast and received modified radical mastectomy (molecular type: hormone-receptor-positive human epidermal growth factor receptor-2 negative). After that, she received postoperative chemotherapy and radiotherapy. After 2 years of tamoxifen adjuvant endocrine treatment, the patient inccurred recurrence with metastasis. PET-CT scanning showed metastasis in the left thoracic wall, the sixth left rib, and the right lower lobe of the lung. Multiple lymph node metastases were observed throughout the body. Palbociclib in combination with an aromatase inhibitor (AI) was used, but the metastatic lesion at the sixth left rib increased than before. Subsequently, the lesion shrunk and the clinical symptoms were relieved, which was considered as a pseudoprogression. Herein, we reported a pseudoprogression in the breast cancer patient after treatment with palbociclib plus AI.